Cancer Home > Folotyn and Breastfeeding
The manufacturer of Folotyn (pralatrexate) recommends that women not breastfeed while undergoing treatment with this drug. Although no studies have been done to determine whether this drug passes through breast milk or if it would harm a nursing infant, there are potentially dangerous side effects associated with Folotyn. If you breastfeed while using this medicine, watch for any potential side effects in your child.
Can Breastfeeding Women Receive Folotyn?Folotyn® (pralatrexate) is a prescription medication used to treat peripheral T-cell lymphoma, a cancer that begins in certain white blood cells called T-cells. At this time, it is unknown if Folotyn passes through breast milk. Therefore, if you are breastfeeding or plan to start, talk to your healthcare provider before receiving the medication.
More Information About Folotyn and BreastfeedingThere is very little information available on the use of Folotyn during breastfeeding, as the drug has not been studied in women who were nursing. Therefore, it is unknown whether it passes through breast milk or whether it would harm a nursing child.
The manufacturer recommends that Folotyn not be given to women who are breastfeeding, as it may cause potentially serious side effects. Until more information is available on Folotyn and breastfeeding, the potential for these side effects to occur in a nursing infant cannot be ruled out. If your healthcare provider recommends that you use this medicine while nursing, you should carefully watch your child for any potential problems.